Skip to main content
Premium Trial:

Request an Annual Quote

German Research Institute Selects Genedata’s Software for Research Use

Premium

Genedata said this week that the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (IKP)in Stuttgart, Germany has licensed the Genedata Expressionist software for use in its pharmacogenomics and oncology translational research projects.

IKP will use Genedata Expressionist, the company said, to process, interpret, and manage terabytes of transcriptomics, genomics, epigenomics, and clinical data from its next-generation sequencing, microarrays, and qPCR experiments. The institute will work with Genedata to customize the software to meet specific requirements for organizing and integrating omics data from its clinical studies. It will also work with the company to develop analytical workflows for identifying mutations associated with poor drug response or prognosis.

"Genedata Expressionist provides a comprehensive platform that allows us to efficiently extract the most relevant scientific and clinical insights from our experiments,” Matthias Schwab, head of IKP Stuttgart, said in a statement. "It is particularly important for us that Genedata Expressionist covers all aspects of NGS data management and analysis, from raw data to results," he added.

The financial details of the agreement were not disclosed.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.